Minosse, C.; Gruber, C.E.M.; Rueca, M.; Taibi, C.; Zaccarelli, M.; Grilli, E.; Montalbano, M.; Capobianchi, M.R.; Antinori, A.; D’Offizi, G.;
et al. Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses 2021, 13, 1151.
https://doi.org/10.3390/v13061151
AMA Style
Minosse C, Gruber CEM, Rueca M, Taibi C, Zaccarelli M, Grilli E, Montalbano M, Capobianchi MR, Antinori A, D’Offizi G,
et al. Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses. 2021; 13(6):1151.
https://doi.org/10.3390/v13061151
Chicago/Turabian Style
Minosse, Claudia, Cesare E. M. Gruber, Martina Rueca, Chiara Taibi, Mauro Zaccarelli, Elisabetta Grilli, Marzia Montalbano, Maria R. Capobianchi, Andrea Antinori, Gianpiero D’Offizi,
and et al. 2021. "Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs" Viruses 13, no. 6: 1151.
https://doi.org/10.3390/v13061151
APA Style
Minosse, C., Gruber, C. E. M., Rueca, M., Taibi, C., Zaccarelli, M., Grilli, E., Montalbano, M., Capobianchi, M. R., Antinori, A., D’Offizi, G., McPhee, F., & Garbuglia, A. R.
(2021). Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses, 13(6), 1151.
https://doi.org/10.3390/v13061151